Abstract 12991: Staged Hybrid Convergent Procedure for Persistent Atrial Fibrillation: Single Center Outcomes From a Community Hospital
| Autor: | Kriti Lnu, Uba C Udeh, David B Loran, Chinmay P Patel, Michael G Link, nikhil P theckumparampil |
|---|---|
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Circulation. 144 |
| ISSN: | 1524-4539 0009-7322 |
| Popis: | Introduction: Hybrid-Convergent procedure(HCP) has been recently approved for treatment of persistent atrial fibrillation(AF). This was studied as a same day procedure which posed significant scheduling challenges with regards to procedure space and personnel. Staging the procedure was more convenient in smaller and busy Community Hospitals like ours. We report our experience with Staged HCP. Methods: We retrospectively analyzed all patients who underwent HCP at our Hospital from January 1,2017 to December 31,2020. Same day HCP were excluded. Outcomes at 6 month and 1 year follow up after the procedure were analyzed. Results: A total of 29 patients with persistent AF underwent Staged HCP. The mean age was 62.3 years with 75.86% being men. Periprocedural and 30 day mortality was 0%. The mean time between epicardial ablation and endocardial ablation was 46.15 days (SD :17.5 days, interquartile range 6-78). Freedom from AF (normal sinus rhythm on electrocardiograms and/or 24 hour monitoring) was seen in 77.78% and 88% patients at 6 months and 1 year respectively. Success of procedure (freedom from AF with maintenance as before procedure, decrease in dose of or complete cessation of Class I/III anti-arrhythmic drug) was seen in 70.4% and 76% at 6 months and 1 year respectively. The de-escalation in treatment (complete cessation or dose reduction of Class I/III anti-arrhythmic drug) at 6 month and 1 year follow up was seen in 57.14% and in 54.55% patients respectively. Conclusions: Staged HCP can be done safely with excellent outcomes on par with results seen in the CONVERGE Clinical Trial |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|